745,079 Shares in Bruker Corporation $BRKR Purchased by Bank of New York Mellon Corp

Key Points

• Bank of New York Mellon acquired 745,079 Bruker shares worth approximately $44.8 million, gaining a 0.49% stake. Institutional investors collectively own 79.52% of the company.
• Analyst sentiment is generally positive, with Bruker holding a consensus “Moderate Buy” rating and an average price target of $56.64, though Citigroup downgraded the stock to “Hold” and cut its target to $53.
• Bruker beat quarterly EPS estimates, reporting $0.49 versus $0.38 expected, while revenue rose 5.2% year over year to $838.5 million. The company also declared a quarterly dividend of $0.05 per share.

Bank of New York Mellon Corp acquired a new stake in Bruker Corporation (NASDAQ:BRKR - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 745,079 shares of the medical research company's stock, valued at approximately $44,839,000. Bank of New York Mellon Corp owned 0.49% of Bruker at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Thrivent Financial for Lutherans boosted its position in shares of Bruker by 561.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 179,792 shares of the medical research company's stock worth $8,470,000 after buying an additional 152,603 shares during the period. Hantz Financial Services Inc. raised its holdings in shares of Bruker by 202.7% in the 4th quarter. Hantz Financial Services Inc. now owns 41,306 shares of the medical research company's stock valued at $1,946,000 after buying an additional 27,659 shares during the period. Fifth Third Bancorp raised its holdings in shares of Bruker by 4,058.3% in the 1st quarter. Fifth Third Bancorp now owns 57,135 shares of the medical research company's stock valued at $2,064,000 after buying an additional 55,761 shares during the period. Franklin Resources Inc. lifted its stake in Bruker by 317.7% during the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company's stock worth $108,796,000 after acquiring an additional 1,756,460 shares in the last quarter. Finally, Amundi boosted its holdings in Bruker by 244.2% during the 1st quarter. Amundi now owns 62,611 shares of the medical research company's stock valued at $2,261,000 after acquiring an additional 44,421 shares during the period. Institutional investors and hedge funds own 79.52% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on BRKR shares. Zacks Research raised Bruker from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 4th. Stifel Nicolaus set a $50.00 price objective on shares of Bruker in a research note on Wednesday, August 5th. Wall Street Zen upgraded shares of Bruker from a "hold" rating to a "buy" rating in a report on Saturday, May 9th. JPMorgan Chase & Co. upped their target price on shares of Bruker from $55.00 to $65.00 and gave the stock an "overweight" rating in a research note on Monday, June 8th. Finally, Citigroup reduced their target price on shares of Bruker from $60.00 to $53.00 and set a "hold" rating on the stock in a report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Bruker presently has a consensus rating of "Moderate Buy" and an average target price of $56.64.

Bruker Stock Performance

Shares of Bruker stock opened at $59.25 on Friday. The business has a 50-day simple moving average of $58.78 and a 200-day simple moving average of $47.94. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. Bruker Corporation has a one year low of $28.53 and a one year high of $65.30. The company has a market cap of $9.03 billion, a PE ratio of -84.64, a P/E/G ratio of 1.75 and a beta of 1.28.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. During the same period in the prior year, the firm posted $0.32 EPS. The company's quarterly revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities research analysts forecast that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 21st. Bruker's dividend payout ratio is -28.57%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source